title: Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome.
abstract: Fragile X syndrome (FXS) is a neurodevelopmental disorder characterized by variable cognitive impairment and behavioral disturbances such as exaggerated fear, anxiety and gaze avoidance. Consistent with this, findings from human brain imaging studies suggest dysfunction of the amygdala. Underlying alterations in amygdala synaptic function in the Fmr1 knock-out (KO) mouse model of FXS, however, remain largely unexplored. Utilizing a combination of approaches, we uncover profound alterations in inhibitory neurotransmission in the amygdala of Fmr1 KO mice. We demonstrate a dramatic reduction in the frequency and amplitude of phasic IPSCs, tonic inhibitory currents, as well as in the number of inhibitory synapses in Fmr1 KO mice. Furthermore, we observe significant alterations in GABA availability, both intracellularly and at the synaptic cleft. Together, these findings identify abnormalities in basal and action potential-dependent inhibitory neurotransmission. Additionally, we reveal a significant neuronal hyperexcitability in principal neurons of the amygdala in Fmr1 KO mice, which is strikingly rescued by pharmacological augmentation of tonic inhibitory tone using the GABA agonist gaboxadol (THIP). Thus, our study reveals relevant inhibitory synaptic abnormalities in the amygdala in the Fmr1 KO brain and supports the notion that pharmacological approaches targeting the GABAergic system may be a viable therapeutic approach toward correcting amygdala-based symptoms in FXS.
authors.affiliation: Center for Neuroscience Research, Children's National Medical Center, Washington DC, 20010, USA.
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: Olmos-Serrano
authors.forename: Scott M
authors.initials: SM
authors.lastname: Paluszkiewicz
authors.forename: Brandon S
authors.initials: BS
authors.lastname: Martin
authors.forename: Walter E
authors.initials: WE
authors.lastname: Kaufmann
authors.forename: Joshua G
authors.initials: JG
authors.lastname: Corbin
authors.forename: Molly M
authors.initials: MM
authors.lastname: Huntsman
mesh_terms: D000679:Amygdala / Q000187:drug effects* / Q000378:metabolism; D000818:Animals; D004195:Disease Models, Animal; D005071:Evoked Potentials; D051860:Fragile X Messenger Ribonucleoprotein 1 / Q000378:metabolism; D005600:Fragile X Syndrome / Q000188:drug therapy* / Q000503:physiopathology*; D018755:GABA Agonists / Q000494:pharmacology*; D005968:Glutamate Decarboxylase / Q000378:metabolism; D066298:In Vitro Techniques; D007395:Interneurons / Q000378:metabolism; D007555:Isoxazoles / Q000494:pharmacology*; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009433:Neural Inhibition / Q000187:drug effects; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D018408:Patch-Clamp Techniques; D009435:Synaptic Transmission / Q000187:drug effects*; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
chemical_list: D051860:Fragile X Messenger Ribonucleoprotein 1; D018755:GABA Agonists; D005968:Glutamate Decarboxylase; D007555:Isoxazoles; D005680:gamma-Aminobutyric Acid; C497684:Fmr1 protein, mouse; C401141:glutamate decarboxylase 2; C015542:gaboxadol